Companies: 10,795·Total market cap: $144.5T
Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

IOVANASDAQHealthcare● Active
$4.12
$-0.11(-2.54%)
Market Cap$1.5B
P/E Ratio
52W High$5.63
52W Low$1.66
Overview

Iovance Biotherapeutics, Inc. (IOVA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

iova · stock forecast · 20 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 20 Wall Street analysts in the past 3 months

SellBuy

Buy

20 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
15
Hold
5
Sell
0
Strong Sell
0
Total: 20 · Buy rate: 75.0%

12-Month Price Target

High

$5.00

Consensus

$4.00

-3.0% upside

Low

$2.00

Median: $5 · Last Close: $4.13

The Iovance Biotherapeutics, Inc. (IOVA) analyst consensus is Buy, based on ratings from 20 Wall Street analysts over the past 3 months. The average 12-month IOVA price target is $4.00, representing -3.0% upside from the current price of $4.13.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $4 (-3.0%)

Consensus Target

$4.00

-3.0% upside

High Target

$5

21.2%

Low Target

$2

-51.5%

Current Price

$4.13

as of today

Based on analyst price targets, the IOVA stock price prediction for the next 12 months ranges from $2 to $5. The consensus IOVA price forecast of $4.00 implies -3.0% upside from the current price of $4.13.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$4.304.31%

1-day model range: $4.26–$4.35. Peak: $4.35 (+4.31%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$2-50.0%
2028$2-63.8%
2029$1-69.2%
2030$1-71.8%
2031-73.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

71%15%14%
10Buy
2Neutral
2Sell
RSI (14)63.6Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · IOVA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$4.13NEUTRAL
MA 10$4.15SELL
MA 20$3.88BUY
MA 50$3.70BUY
MA 100$3.50BUY
MA 200$2.91BUY
Current $IOVA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$4.14SELL
EMA 10$4.08BUY
EMA 20$3.96BUY
EMA 50$3.77BUY
EMA 100$3.51BUY
EMA 200$3.40BUY
Current $IOVA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Chardan Capital2026-05-07
Maintains
BuyBuy
Chardan Capital2026-04-10
Maintains
BuyBuy
UBS2026-03-05
Maintains
NeutralNeutral
Citizens2026-03-03
Upgrade ↑
Market PerformMarket Outperform
Barclays2026-02-25
Maintains
OverweightOverweight
Citizens2026-02-25
Upgrade ↑
Market PerformMarket Outperform
Barclays2025-12-17
Maintains
OverweightOverweight
Barclays2025-11-24
Maintains
OverweightOverweight
Chardan Capital2025-11-06
Maintains
BuyBuy
HC Wainwright & Co.2025-10-29
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Iovance Biotherapeutics, Inc. (IOVA) stock. Of the recent 150 rating actions, 9 were upgrades and 11 were downgrades. 20 analysts currently cover IOVA.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

IOVA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$360M

↓ 50.0% YoY

Revenue Next Year

$494M

↑ 37.2% YoY

EPS This Year

$-0.55

EPS Next Year

$-0.31

↓ 43.7% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast IOVA EPS of $-0.55 for the current fiscal year, based on estimates from 6 analysts. The IOVA revenue forecast is $360M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The IOVA stock forecast is supported by two independent data sources: analyst consensus ratings from 20 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IOVA price target is $4.00 (-3.0% upside), with an analyst consensus of Buy.

The IOVA short-term stock prediction for tomorrow is $4.30 (+4.31%). The IOVA stock price prediction for 2027 estimates an average of $2. The IOVA stock prediction for 2030 projects a range of $1–$1.

Iovance Biotherapeutics, Inc. trades on NASDAQ under the ticker IOVA. The IOVA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

IOVA forecast · 8 questions

According to 20 Wall Street analysts, the average 12-month IOVA price target is $4.00, with a high forecast of $5.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies -3.0% potential upside from the current price of $4.13.

IOVA price targetWhat is IOVA price targetIOVA analyst price targetIOVA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.